Immune Response Corp. announced that it has been granted apatent by the European Patent Office covering vaccines andmethods for the prevention or treatment of certainautoimmune diseases, such as rheumatoid arthritis andmultiple sclerosis.
The Carlsbad, Calif., company (NASDAQ:IMNR) said that it hasidentified autoreactive T cells that it believes initiate the attackagainst normal tissue, resulting in certain autoimmunediseases. Immune Response is conducting Phase I clinicals ontwo rheumatoid arthritis therapeutics based on the technologycovered by the patent. The company hopes to begin Phase Iclinicals of a multiple sclerosis therapeutic in early 1994.
Immune Response's stock closed at $11.88, up 50 cents.
(c) 1997 American Health Consultants. All rights reserved.